IMVT - Immunovant, Inc.
IEX Last Trade
26.005
0.075 0.288%
Share volume: 21,784
Last Updated: Thu 26 Dec 2024 08:30:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$25.93
0.07
0.29%
Fundamental analysis
25%
Profitability
25%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
1.24%
1 Month
-3.98%
3 Months
-7.88%
6 Months
0.08%
1 Year
-40.98%
2 Year
60.69%
Key data
Stock price
$26.00
DAY RANGE
$25.64 - $26.41
52 WEEK RANGE
$25.39 - $45.58
52 WEEK CHANGE
-$38.42
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Peter Salzmann
Region: US
Website: immunovant.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: immunovant.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
Recent news